LPOXY Therapeutics is developing a convenient, orally administered capsule to deliver OXYGEN directly to the bowel to help those with inflammatory bowel diseases
Location: United States
Total raised: $28M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 03.09.2025 | Series A | $28M | - |
Mentions in press and media 3
| Date | Title | Description |
| 06.09.2025 | LPOXY Therapeutics: $28 Million Series A Advanced To Launch Pivotal Trial For C. Difficile Prevention | LPOXY Therapeutics, a clinical-stage biopharmaceutical company focused on preventing Clostridioides difficile infections without antibiotics, has taken a significant step forward in its development journey. The company has signed a term she... |
| 03.09.2025 | LPOXY Raises Funding from 5 Horizons Ventures | LPOXY, a Platte City, MO-based clinical-stage biopharmaceutical company developing a novel non-antibiotic therapy, raised an undisclosed amount in funding. The round was led by 5 Horizons Ventures in support of a $28M Series A financing. Th... |
| - | LPOXY Therapeutics | “LPOXY Therapeutics is developing a convenient, orally administered capsule to deliver OXYGEN directly to the bowel to help those with inflammatory bowel diseases” |